Cocrystal Pharma Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	December 31,
	2023	2022
Operating activities:
Net loss	$(17,984)	$(38,837)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation-and-amortization expense	189	185
Right of use assets	(1,577)	203
Loss on impairment of goodwill	-	19,092
Stock-based compensation	801	855
Change in operating lease liabilities	1,563	(209)
Change in fair value of derivative liabilities	-	(12)
Changes in operating assets and liabilities:
Tax credit receivable	(174)	(716)
Prepaid expenses and other current assets	470	(1,675)
Accounts payable and accrued expenses	2,046	(321)
Net cash used in operating activities	(14,666)	(21,435)
Investing activities:
Purchases of property and equipment	(118)	(74)
Net cash used in investing activities	(118)	(74)
Financing activities:
Payments of finance lease obligations	(7)	(27)
Proceeds from sale of common stock, net of transaction costs	4,000	-
Net cash provided by (used in) financing activities	3,993	(27)
Net decrease in cash and restricted cash	(10,791)	(21,536)
Cash and restricted cash at beginning of period	37,219	58,755
Cash and restricted cash at end of period	$26,428	$37,219

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.